mBio

SEP 8, 2026 · JOURNAL ARTICLE

Purine and pyrimidine analogs differentially regulate cell wall precursor biosynthesis to control β-lactam susceptibility in methicillin-resistant Staphylococcus aureus

mBio

In vitro mechanistic study demonstrating synergy between pyrimidine analogs and β-lactams in MRSA via cell wall precursor pathway modulation, with potential for repurposing anticancer drugs, but requiring in vivo validation before clinical application.

SEP 3, 2026 · JOURNAL ARTICLE

A uniquely human sebum lipid drives streptococcal skin infection severity

mBio

A mechanistic study in a murine model identifying a host-pathogen interaction mechanism; the finding requires human clinical validation and does not yet establish clinical impact or therapeutic utility.

AUG 10, 2026 · JOURNAL ARTICLE

Deletion of the Salmonella pathogenicity island 2 gene, spiC, in attenuated Salmonella Typhimurium VNP20009 optimizes its potential for bacterial schwannoma therapy

mBio

Preclinical murine model study of engineered bacterial strains with no human data, efficacy endpoints, or quantified effect sizes reported.

AUG 10, 2026 · JOURNAL ARTICLE

Identification of SKI-II as a host-protective immunomodulator against Staphylococcus aureus infection

mBio

Early-stage mechanistic discovery in model organisms and cultured cells identifying a candidate compound and signaling pathway, without in vivo efficacy data or clinical translation.

AUG 3, 2026 · JOURNAL ARTICLE

Nonantibiotic-driven evolution reveals rare but predictable routes to broad antibiotic resistance

mBio

In vitro experimental evolution study identifying mechanistic routes to resistance but without clinical validation, patient data, or definitive risk quantification in real-world settings.

JUL 30, 2026 · JOURNAL ARTICLE

Approaching the post-antibiotic era: phage therapy current practices and future horizons

mBio

A narrative review synthesizing existing clinical evidence and expert recommendations on phage therapy applications, potential, and research gaps rather than reporting original trial data.